Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551795 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL1953071 | 0.80 | — | — | |
| SCHEMBL377128 | 0.76 | — | — | |
| SCHEMBL6801360 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL3320020 | 0.74 | — | — | |
| SCHEMBL58748 | 0.73 | GRM4 (0.45) | — | |
| Bromide SCHEMBL4412518 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL30866177 | 0.72 | GRM4 (0.39) | — | |
| SCHEMBL27410335 | 0.72 | — | — | |
| SCHEMBL293968 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587500-A2 | EXCITONICALLY COUPLED COACERVATES VIA LIQUID/LIQUID PHASE SEPARATION AND METHODS FOR MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024059678-A2 | EXCITONICALLY COUPLED COACERVATES VIA LIQUID/LIQUID PHASE SEPARATION AND METHODS FOR MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| US-7977334-B2 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity modulator, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| CN-101675050-A | Purines as cysteine protease inhibitors | GLAXO GROUP LTD | 2010-03-17 | — | — | CN | disclosed |
| WO-2004039784-A1 | NOVEL PHENYLETHANOLAMINE DERIVATIVES AND THE USE OF THE SAME AS BETA-3-AGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
| EP-1373224-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020198198-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002074754-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-0777653-B1 | DIHYGROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER (US) | 2001-08-22 | — | — | EP | disclosed |
| US-5859011-A | Dihydropyridine derivatives as bradykinin antagonist | PFIZER INC. (US) | 1999-01-12 | — | — | US | disclosed |
| CN-1175252-A | Imidazole derivatives as protein kinase inhibitors in particular egf-rthyrosine kinase | HOFFMANN LA ROCHE (CH) | 1998-03-04 | — | — | CN | disclosed |
| EP-0777653-A1 | DIHYGROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996006083-A1 | 2-(PIPERAZINYL-1-CARBONYLMETHYL)-1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1996-02-29 | — | — | WO | disclosed |
| WO-1996006082-A1 | DIHYDROPYRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | PFIZER INC. (US) | 1996-02-29 | — | — | WO | disclosed |